Royalty Payments and Reporting. 4.1 Royalty payments from MSP to LICENSOR shall be made monthly within fifteen (15) days after the end of each calendar month for which royalty payments are due following the Effective Date with seventy-five (75) percent of the respective royalty payment paid to XXXXXXX and twenty-five (25) percent paid to XXXXXXXXX. Royalty payments for each calendar month period shall be based on Net Sales of those Licensed Services invoiced by MSP during that period. All such payments shall be accompanied by a full and complete report detailing the computation of the royalty payment. Payments shall be made in U S. Dollars. For purposes of computing royalties payable hereunder, amounts in currencies other than U.S. Dollars will be converted into U S Dollars using as a rate of exchange for such payments the midpoint between the buying and selling rate for U S Dollars as quoted by Texas Commerce Bank in Houston. Texas (or any other bank agreeable to the parties should this bank cease operations) at the close of business on the last business day of the calendar month for which royalties are due.
Royalty Payments and Reporting. Buyer shall calculate all amounts payable to Seller pursuant to Section 5.2 at the end of each Calendar Quarter and shall provide a written estimate of such amount, including the associated assumptions utilized for such estimate, within [***] days after the end of such Calendar Quarter. Buyer shall pay Seller the royalty amounts due with respect to a given Calendar Quarter within [***] days after the end of such Calendar Quarter. Each payment of royalties due to Seller shall be accompanied by a statement of the amount of gross sales and Net Sales of each Product in each country during the applicable Calendar Quarter (including such amounts expressed in local currency and as converted to Dollars) and a calculation of the amount of royalty payment due on such Net Sales for such Calendar Quarter (including all deductions and reductions).
Royalty Payments and Reporting. Gilead shall calculate all amounts payable to Precision pursuant to Section 5.4.1 at the end of each Calendar Quarter. Gilead shall pay to Precision the royalty amounts due with respect to a given Calendar Quarter within [***] after the end of such Calendar Quarter. Each payment of royalties due to Precision shall be accompanied by a statement of the amount of gross sales and Net Sales (including applicable deductions) of each Licensed Product, in each country of the Territory during the applicable Calendar Quarter (including such amounts expressed in local currency and as converted to Dollars), a calculation of the amount of royalty payment due on such Net Sales for such Calendar Quarter, and details on the determination of incremental royalty rates including the aggregation of Licensed Products into Licensed Product Families.
Royalty Payments and Reporting. (a) Beginning on the License Effective Date, Par shall pay Sucampo a royalty of […***…] of the Licensed Products sold during the term of this Agreement, which term continues until each of the Sucampo Patents has expired, or each has been dedicated to the public or disclaimed pursuant to 35 USC § 253, or every claim that was asserted against Par in the Patent Litigation has been held invalid or unenforceable in a Final Court Decision, unless otherwise provided by this Section 3.13. If within two years prior to the License Effective Date, (x) Sucampo or an Affiliate of Sucampo, Commercially Markets in the Territory for the first time, either alone or in partnership with another Person, a new lubiprostone-containing drug product indicated for the treatment of constipation or irritable bowel syndrome under a marketing approval that is obtained for the first time after the Effective Date of this Agreement and (y) the total prescriptions for the AMITIZA® Oral Capsule Products (in the aggregate) for any quarter during the two year window decline by at least […***…] ([…***…]%) from the average quarterly IMS NPA total prescriptions for the AMITIZA® Oral Capsule Products (in the aggregate), as determined on a *Confidential Treatment Requested rolling basis by dividing such total prescriptions for the immediately preceding twelve (12) month period by four (4), Par shall as of the License Effective Date pay Sucampo a royalty of […***…] of the Licensed Products sold during the term of this Agreement, which term continues until each of the Sucampo Patents has expired, or each has been dedicated to the public or disclaimed pursuant to 35 USC § 253, or every claim that was asserted against Par in the Patent Litigation has been held invalid or unenforceable in a Final Court Decision, unless otherwise provided by this Section 3.13.
Royalty Payments and Reporting. Gilead will calculate all amounts payable to Nurix pursuant to this Section 11.8 (Royalties) at the end of each Calendar Quarter. Gilead will pay to Nurix the royalty amounts due, less any applicable withholding tax that is required by Applicable Law in accordance with Section 11.10.3 (Taxes; Withholding), with respect to a given Calendar Quarter within sixty (60) days after the end of such Calendar Quarter. Each payment of royalties due to Nurix will be accompanied by a royalty report stating the amount of gross sales and Net Sales of each Licensed Product in each country of the Territory during the applicable Calendar Quarter and a detailed calculation of the amount of royalty payment due on such Net Sales for such Calendar Quarter (including all Net Sales reductions).
Royalty Payments and Reporting. (a) Beginning on any License Launch Date that is prior to the date specified in Section 2(a), Par shall pay Sucampo […***…] of Par’s ANDA Product sold during the term of this Agreement for all such Gross Profits […***…], which term continues until each of the Sucampo Patents has expired, or each has been dedicated to the public or disclaimed pursuant to 35 USC § 253, or every claim that was asserted against Par in the Patent Litigation has been held invalid or unenforceable in a Final Court Decision, unless otherwise provided by this Section 5.
Royalty Payments and Reporting. Licensee will calculate all amounts payable to Relay pursuant to Section 11.6 at the end of each Calendar Quarter and will pay to Relay the royalty amounts due with respect to a given Calendar Quarter within [***] after the end of such Calendar Quarter. Each payment of royalties due to Relay will be accompanied by a statement of the amount of Sales and Net Sales of each Licensed Product in each country in the Royalty Territory or Territory, as applicable, during the applicable Calendar Quarter (including such amounts expressed in local currency and as converted to Dollars) and a detailed calculation of the amount of royalty payment due on such Net Sales for such Calendar Quarter (including all deductions and reductions).
Royalty Payments and Reporting. 12.1. In partial consideration of the rights granted pursuant to Articles III through IX and Article XI of this Agreement, Elastic shall pay to Nortel Networks:
Royalty Payments and Reporting. Sanofi will calculate all amounts payable to IGM pursuant to this Section 9.5 (Royalties) at the end of each Calendar Quarter. Within [***], Sanofi shall provide to IGM a written, [***], on a [***] basis, of Net Sales of such Licensed Product in the Royalty Territory during the preceding Calendar Quarter and the royalties payable by Sanofi to IGM pursuant to Section 9.5 (Royalties) [***], Sanofi will, with respect to each Calendar Quarter (or portion thereof), prepare a written report showing, on a country-by-country, Licensed Product-by-Licensed Product basis and Collaboration Target-by-Collaboration Target basis in the applicable Royalty Territory: (a) [***], (b) [***], (c) [***], and (d) [***] (each, a “Royalty Report”), and Sanofi shall provide to IGM each such Royalty Report within [***]. Sanofi shall provide such Royalty Reports for so long as any Royalty Term remains in effect. [***].
Royalty Payments and Reporting. Sanofi will calculate all amounts payable to Nurix pursuant to this Section 11.7 (Royalties) at the end of each Calendar Quarter. Sanofi will pay to Nurix the royalty amounts due, less any applicable withholding tax that is required by Applicable Law in accordance with Section 11.10.5 (Taxes; Withholding), with respect to a given Calendar Quarter within [*] days after the end of such Calendar Quarter. Commencing as of the First Commercial Sale for a Licensed Product Sanofi will, with respect to each Calendar Quarter (or portion thereof), provide a written report showing (a) aggregate Net Sales of such Licensed Product that are royalty bearing and the royalties due thereon for such Calendar Quarter, (b) the withholding taxes, if any, required by law to be deducted in respect of such royalties, and (c) the exchange rates used in determining the royalty amount expressed in Euro (each, a “Royalty Report”), within [*] days after the end of such Calendar Quarter. Sanofi shall provide such Royalty Reports for so long as any Royalty Term remains in effect for a given Licensed Product.
